Sharechat Logo

Greenfern Industries attains important industry certificati

Wednesday 22nd June 2022

Text too small?

Greenfern Industries Limited (GFI:NZX) is pleased to announce it has attained its globally-recognised GACP (Good Agriculture and Collection Practice) certification for its cultivation facility based in Normanby, Taranaki.

“This is a milestone that the team has been working towards for some time since commencing cultivation and research and development in our pilot stage one facility,” said Greenfern’s managing director Dan Casey.

GACP guidelines were developed to create a single supranational framework to ensure appropriate and consistent quality in the cultivation and production of medicinal plant and herbal substances. They were developed by the World Health Organisation (WHO) in 2003 with the aim of improving the quality of medicinal plants being used in herbal medicines in the commercial market.

Greenfern’s certification was undertaken by Control Union Medicinal Cannabis Standards (CUMCS). Control Union Israel was one of the partners which formulated the Israeli Cannabis Standard, which is a global standard. Since then, they have been involved with the development of the Medical Cannabis Standard GAP.

The scope of CUMCS-GAP covers medical cannabis propagation, cultivation and post-harvest processes and is fully compliant with both the WHO and European Medicines Agency (EMA) GACP guidelines. Certified organisations such as Greenfern receive both CUMCS-GAP certificate and GACP compliance certificate for both the WHO as well as EMA GACP guidelines.

“Having the certification is essentially a prerequisite to connect with overseas buyers of medicinal cannabis before they will look to receiving exported cannabis from an overseas jurisdiction. This, along with New Zealand’s medicinal cannabis minimum quality standards of testing for export, make this both a difficult and yet extremely important certification for the company.

“Our GACP certification should help progress further talks and securing binding offtake contracts with overseas buyers for our medicinal cannabis grown right here in Taranaki,” said Casey

As of June 2021, New Zealand’s Ministry for Foreign Affairs and Trade reported Germany as one of the largest medicinal cannabis markets in Europe and it continues to grow. They state that the average farm gate price for medical cannabis will be €2.20/g, or NZD$3.65.

“Greenfern can grow, dry, trim and package their cannabis for a much lower cost than that. This is mostly due to the fact that having our own hydroelectric power station and utilising power at cost price helps keep the cultivation costs to a minimum. While electricity costs make up a large portion of your operating expense when growing cannabis in a fully enclosed indoor environment, this is a real long-term strategic benefit for Greenfern. We are excited to scale up our stage two facility in the near future,” said Casey.

-Ends-



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

4th July 2022 Morning Report
BIF - Acquires shares in Hot Lime Labs
RUA - Cann Group granted TGA GMP for Mildura facility
AFI - Invitation to Results Webcast
PFI Share Buyback Programme to Pause
Greenfern Industries Limited ("GFI") - Late Annual Report
FSF - Monthly Allotment/ Redemption Notice
1st July 2022 Morning Report
General Capital Releases 2022 Annual Report
Fonterra, NZX, EEX confirm GDT strategic partnership